Potential of porous poly-D,L-lactide-co-glycolide particles as a carrier for recombinant human bone morphogenetic protein-2 during osteoinduction in vivo

被引:0
|
作者
Boyan, BD
Lohmann, CH
Somers, A
Niederauer, GG
Wozney, JM
Dean, DD
Carnes, DL
Schwartz, Z
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Orthopaed, San Antonio, TX 78284 USA
[2] Univ Texas, Hlth Sci Ctr, Dept Periodont, San Antonio, TX 78284 USA
[3] Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA
[4] OsteoBiol Inc, San Antonio, TX USA
[5] Genet Inst, Andover, MA USA
[6] Univ Texas, Hlth Sci Ctr, Dept Endodont, San Antonio, TX 78284 USA
[7] Hebrew Univ Jerusalem, Dept Periodont, Jerusalem, Israel
来源
关键词
recombinant human bone morphogenetic protein-2; osteoinduction; bone graft substitute; poly-D; L-lactide-co-glycolide copolymer; bone morphogenetic protein carrier;
D O I
10.1002/(SICI)1097-4636(199907)46:1<51::AID-JBM6>3.3.CO;2-9
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Several different biodegradable bone graft materials are in clinical or preclinical use for the repair of bone defects in orthopedics, maxillofacial surgery, and periodontics. This study tested the hypothesis that poly-D,L-lactide-co-glycolide copolymer (PLG) can be used as an effective carrier of recombinant human bone morphogenetic protein-2 (rhBMP-2) and that the composite has osteoinductive ability. Porous PLG rods were shredded to a particle size ranging from 250 to 850 mu m Active and inactive demineralized freeze-dried bone allografts (DFDBA) with a comparable particle size were used as positive and negative controls, respectively. PLG particles were treated with vehicle or with 5 or 20 mu g rhBMP-2. DFDBA and PLG particles were placed in gelatin capsules, mixed with vehicle or rhBMP-2, and implanted at intramuscular sites in male Nu/Nu (nude) mice. Each mouse underwent bilateral implantation with implants of the same formulation, resulting in five groups of four mice per group: active DFDBA, inactive DFDBA, PLG, PLG + 5 mu g rhBMP-2, and PLG + 20 mu g rhBMP-2. After 56 days, the implants were recovered and processed for histology. Bone induction was assessed by use of a semiquantitative scoring system based on the amount of new bone formed in representative histological sections. Histomorphometry was also used to measure the area of new bone formed and the area of residual implant material. The results showed that active DFDBA induced the formation of ossicles containing new bone with bone marrowlike tissue, whereas inactive DFDBA or PLG particles alone did not induce new bone. The addition of rhBMP-2 to PLG particles resulted in new bone formation that had a greater bone induction score than active DFDBA. Moreover, the histomorphometric analysis showed that the addition of rhBMP-2 to PLG particles induced the formation of a greater area of new bone and bone marrowlike tissue than active DFDBA. The resorption of the PLG particles was markedly increased with the addition of rhBMP-2, suggesting that rhBMP-2 may attract and regulate resorptive cells at the implantation site. The results of the present study indicate that PLG copolymers are good carriers for BMP and promote the induction of new bone formation. Further, the PLG copolymers with rhBMP-2 had a greater effect in inducing new bone formation and resorbing the implanted material than active DFDBA alone. (C) 1999 John Wiley & Sons, Inc.
引用
收藏
页码:51 / 59
页数:9
相关论文
共 50 条
  • [21] Magnetite/poly(D,L-lactide-co-glycolide) and hydroxyapatite/poly(D,L-lactide-co-glycolide) prepared by w/o/w emulsion technique for drug carrier: physical characteristic of composite nanoparticles
    Kittima Bootdee
    Brian P. Grady
    Manit Nithitanakul
    Colloid and Polymer Science, 2017, 295 : 2031 - 2040
  • [22] Magnetite/poly(D,L-lactide-co-glycolide) and hydroxyapatite/poly(D,L-lactide-co-glycolide) prepared by w/o/w emulsion technique for drug carrier: physical characteristic of composite nanoparticles
    Bootdee, Kittima
    Grady, Brian P.
    Nithitanakul, Manit
    COLLOID AND POLYMER SCIENCE, 2017, 295 (10) : 2031 - 2040
  • [23] Osteotropic poly(D,L-lactide-co-glycolide)-alendronate nanoparticles for the treatment of bone cancer
    Cenni, Elisabetta
    Salerno, Manuela
    Fotia, Caterina
    Avnet, Sofia
    Granchi, Donatella
    Castelli, Francesco
    Micieli, Dorotea
    Pignatello, Rosario
    Capulli, Mattia
    Rucci, Nadia
    Teti, Anna
    Baldini, Nicola
    CANCER TREATMENT REVIEWS, 2008, 34 : S74 - S74
  • [24] Osteoinduction by recombinant human bone morphogenetic protein-2 in muscles of non-human primates
    Kusumoto, K
    Bessho, K
    Fujimura, K
    Akioka, J
    Okubo, Y
    Wang, Y
    Iizuka, T
    Ogawa, Y
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2002, 30 (03) : 251 - 259
  • [25] Entrapment of Protein Using Electrosprayed Poly(D,L-lactide-co-glycolide) Microspheres with a Porous Structure for Sustained Release
    Paik, Dong-Hyun
    Choi, Sung-Wook
    MACROMOLECULAR RAPID COMMUNICATIONS, 2014, 35 (11) : 1033 - 1038
  • [26] Mathematical modelling of the solubility of supercritical CO2 in poly(L-lactide) and poly(D,L-lactide-co-glycolide)
    Aionicesei, Elena
    Skerget, Mojca
    Knez, Zeljko
    JOURNAL OF SUPERCRITICAL FLUIDS, 2009, 50 (03): : 320 - 326
  • [27] A new recombinant human bone morphogenetic protein-2 carrier for bone regeneration
    Yokota, S
    Sonohara, S
    Yoshida, M
    Murai, M
    Shimokawa, S
    Fujimoto, R
    Fukushima, S
    Kokubo, S
    Nozaki, K
    Takahashi, K
    Uchida, T
    Yokohama, S
    Sonobe, T
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 223 (1-2) : 69 - 79
  • [28] Bone morphogenetic protein-2 application by a poly(D,L-lactide)-coated interbody cage: in vivo results of a new carrier for growth factors
    Kandziora, F
    Bail, H
    Schmidmaier, G
    Schollmeier, G
    Scholz, M
    Knispel, C
    Hiller, T
    Pflugmacher, R
    Mittlmeier, T
    Raschke, M
    Haas, NP
    JOURNAL OF NEUROSURGERY, 2002, 97 (01) : 40 - 48
  • [29] Osteoinduction by recombinant human bone morphogenetic protein-2 at intramuscular, intermuscular, subcutaneous and intrafatty sites
    Okubo, Y
    Bessho, K
    Fujimura, K
    Konishi, Y
    Kusumoto, K
    Ogawa, Y
    Iizuka, T
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2000, 29 (01) : 62 - 66
  • [30] Slow and continuous application of human recombinant bone morphogenetic protein via biodegradable poly(lactide-co-glycolide) foamspheres
    Weber, FE
    Eyrich, G
    Grätz, KW
    Maly, FE
    Sailer, HF
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2002, 31 (01) : 60 - 65